Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 19;ciaa461.
doi: 10.1093/cid/ciaa461. Online ahead of print.

Antibody Detection and Dynamic Characteristics in Patients With COVID-19

Affiliations
Free PMC article

Antibody Detection and Dynamic Characteristics in Patients With COVID-19

Fei Xiang et al. Clin Infect Dis. .
Free PMC article

Abstract

Background: The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed.

Methods: The antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate.

Results: The seroconversion of specific IgM and IgG antibodies were observed as early as the 4th day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity.

Conclusions: The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.

Keywords: COVID-19; ELISA; SARS-CoV-2; diagnosis; serological test.

Similar articles

See all similar articles

Cited by 2 articles

  • [Statement of the Austrian Society of Pneumology (ASP)].
    Flick H, Arns BM, Bolitschek J, Bucher B, Cima K, Gingrich E, Handzhiev S, Hochmair M, Horak F, Idzko M, Jaksch P, Kovacs G, Kropfmüller R, Lamprecht B, Löffler-Ragg J, Meilinger M, Olschewski H, Pfleger A, Puchner B, Puelacher C, Prior C, Rodriguez P, Salzer H, Schenk P, Schindler O, Stelzmüller I, Strenger V, Täubl H, Urban M, Wagner M, Wimberger F, Zacharasiewicz A, Zwick RH, Eber E. Flick H, et al. Wien Klin Mag. 2020 May 18:1-22. doi: 10.1007/s00740-020-00350-4. Online ahead of print. Wien Klin Mag. 2020. PMID: 32427192 Free PMC article. Review. German.
  • [COVID-19 in hospitalized children and adolescents].
    Streng A, Hartmann K, Armann J, Berner R, Liese JG. Streng A, et al. Monatsschr Kinderheilkd. 2020 Apr 21:1-12. doi: 10.1007/s00112-020-00919-7. Online ahead of print. Monatsschr Kinderheilkd. 2020. PMID: 32317808 Free PMC article. Review. German.
Feedback